Market snapshot
Eli Lilly Co. moved higher today, trading at $1,115.68 and marking a 46.7% gain over the past 12 months. Novo Nordisk A/S, by contrast, is trading at $44.28 and is down 3.1% on a 1-year basis, including a roughly -6% drop on the day. The split underscores a widening divergence in investor expectations and momentum between the two companies.
Box score: headline metrics
- Eli Lilly - Price: $1,115.68; 1-year total return: +46.7%; fair value upside: 8.4%.
- Novo Nordisk - Price: $44.28; 1-year total return: -3.1%; fair value upside: 56.0%.
How the fundamentals compare
The divergence is visible across growth, profitability, and valuation. Revenue expectations for Lilly call for a 30.3% increase next year, supported by strong clinical momentum around obesity treatment retatrutide and the prospect of a guidance raise. Novo, in contrast, is projected to face a -6.5% revenue decline next year and has trimmed its outlook repeatedly, including a fourth guidance cut within a 12-month span.
On profitability both companies show similar margin footprints, with Lilly recording a 48.6% EBITDA margin and Novo slightly higher at 49.6%. But earnings-per-share trajectories differ sharply: Lilly’s EPS is expected to climb 49.3% next year while Novo’s EPS is forecast to fall by 6.6%.
Valuation captures the market’s posture: Lilly is trading at a 32.6x forward price-to-earnings multiple, a premium that reflects strong growth visibility, while Novo sits at 14.3x forward P/E, signaling discount pricing amid weaker near-term prospects. Lilly’s trailing P/E is noted at 52.3x, illustrating how recent gains have stretched historical multiples.
Pair trade dynamics
On paper, the conventional long-Novo/short-Lilly pair trade looks appealing because it bets on mean reversion between an out-of-favor stock and a market darling. But the current setup is not symmetric. Lilly’s premium valuation leaves limited margin for execution risk; an earnings or guidance miss could pressure shares given how much growth is priced in. Novo’s valuation and large fair-value upside imply ample potential return, but that payoff depends entirely on stabilization after multiple guidance cuts, leadership changes, and workforce reductions.
Near-term catalysts and headlines
- Both companies report quarterly results on August 5. Bernstein expects Lilly to raise guidance by $1.5 billion; for Novo, the immediate objective is simply to avoid further downgrades. (Read more - Aug 2, 2026)
- Lilly’s retatrutide posted stronger Phase 3 obesity results versus Novo’s Wegovy, showing 22.6% weight loss compared with roughly 15% for Wegovy, and an FDA filing for retatrutide is planned for Q1 2027.
- Novo is facing a securities fraud class action related to CagriSema disclosures. (Read more - Jul 28, 2026)
Interpretation for investors
The trade is essentially a conditional one: if Novo can show signs of halting declines and rebuilding guidance credibility, the undervaluation could produce a sharp rebound given the 56.0% fair-value upside. If Novo continues to disappoint, the downside risk remains material despite the cheap valuation. Lilly, meanwhile, is the momentum leader but is priced for near-perfection; small execution slips could have outsized impact on returns.
Bottom line
The split between Eli Lilly and Novo Nordisk today is a snapshot of asymmetric risk and reward. The classic pairs idea requires more than relative mispricing—it requires a credible path to stabilization for the beaten stock. That path is the single pivot that determines whether the pair trade becomes a profitable hedge or an asymmetric gamble.
Note: All figures and projections cited are drawn from the accompanying market data and analyst estimates referenced above.